Dr Spencer Collis
Clinical Medicine, School of Medicine and Population Health
Reader in Genome Stability
Head of the Genome Stability Group
+44 114 215 9043
Full contact details
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Profile
-
For enquiries please contact - ClinMed-Operational@sheffield.ac.uk
1994 - 1997
BSc (Hons): Biochemistry, UMIST1997 - 2000
PhD: Oncology, CRUK Paterson Institute for Cancer Research2001 - 2004
Post-Doc: Prof. Theodore DeWeese laboratory, Johns Hopkins University2004 - 2009
Post-Doc: Dr Simon Boulton laboratory, Clare Hall Laboratories, CRUK London Research Institute2009 - 2013
Group leader: Institute for Cancer Studies, University of Sheffield2013 - 2015
Senior Lecturer: Academic unit of Molecular Oncology, Department of Oncology, University of Sheffield2016 -
Reader: Academic unit of Molecular Oncology, Department of Oncology, University of SheffieldCurrent PhD Opportunities:
- Research interests
-
The overarching research goals of the Collis laboratory is to identify and functionally characterise novel factors that are important for the maintenance of genome integrity in human cells. This research also aims to establish if such factors are novel drug targets and/or biomarkers that can be exploited to improve the treatment of diseases such as cancer, either alone, or in combination with existing chemo- and/or radio-therapeutic regimes. To achieve this, the Collis group collaborate with a range of national and international scientists and clinicians to maximise the potential therapeutic impact of their basic biological discoveries.
Funding Sources
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Development and optimisation of Tumour Treating Fields (TTFields) delivery within 3D primary glioma stem cell-like models of spatial heterogeneity. Cancers, 16(5). View this article in WRRO
- DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells. British Journal of Cancer.
- Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients. F1000Research, 12.
- Precision oncology using ex vivo technology: a step towards individualised cancer care?. Expert Reviews in Molecular Medicine, 24. View this article in WRRO
- DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.. Molecular Oncology, 16(1), 11-41. View this article in WRRO
- Identification and validation of ERK5 as a DNA damage modulating drug target in glioblastoma. Cancers, 13(5). View this article in WRRO
- Tumour treating fields therapy for glioblastoma: current advances and future directions.. Br J Cancer, 124(4), 697-709.
- MRNIP is a replication fork protection factor.. Sci Adv, 6(28), eaba5974.
- The 'Ins and Outs' of Early Preclinical Models for Brain Tumor Research: Are They Valuable and Have We Been Doing It Wrong?. Cancers (Basel), 11(3).
- The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response.. Oncotarget, 9(50), 29508-29524.
- The bornavirus-derived human protein EBLN1 promotes efficient cell cycle transit, microtubule organisation and genome stability.. Sci Rep, 6, 35548.
- Human CDK18 promotes replication stress signaling and genome stability.. Nucleic Acids Res, 44(18), 8772-8785.
- MRNIP/C5orf45 Interacts with the MRN Complex and Contributes to the DNA Damage Response.. Cell Rep, 16(10), 2565-2575.
- Ciliogenesis and the DNA damage response: a stressful relationship.. Cilia, 5, 19.
- The leukemia-associated Rho guanine nucleotide exchange factor LARG is required for efficient replication stress signaling.. Cell Cycle, 13(21), 3450-3459.
- FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.. Oncotarget, 5(15), 6414-6424.
- Ccdc13 is a novel human centriolar satellite protein required for ciliogenesis and genome stability.. J Cell Sci, 127(Pt 13), 2910-2919.
- The centriolar satellite protein Cep131 is important for genome stability.. J Cell Sci, 125(Pt 20), 4770-4779.
All publications
Journal articles
- Development and optimisation of Tumour Treating Fields (TTFields) delivery within 3D primary glioma stem cell-like models of spatial heterogeneity. Cancers, 16(5). View this article in WRRO
- Inhibition of ATR opposes glioblastoma invasion through disruption of cytoskeletal networks and integrin internalisation via macropinocytosis. Neuro-Oncology, noad210.
- DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells. British Journal of Cancer.
- DEfiNING SPATIAL HETEROGENEITY OF A NOVEL LIVING BIOBANK OF POST-SURGICAL RESIDUAL GLIOBLASTOMA TO DEVELOP STRATEGIES FOR TARGETED THERAPY. Neuro-Oncology, 25(Supplement_3), iii14-iii14.
- Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients. F1000Research, 12.
- Development of a personalised device for systemic magnetic drug targeting to brain tumours. Nanotheranostics, 7(1), 102-116. View this article in WRRO
- STEM-02. GENERATION AND CHARACTERISATION OF A LIVING BIOBANK OF POST-SURGICAL RESIDUAL GLIOBLASTOMA TO IDENTIFY NOVEL THERAPEUTIC TARGETS. Neuro-Oncology, 24(Supplement_7), vii31-vii31.
- DNAR-12. COMBINING TUMOUR TREATING FIELDS WITH THERAPEUTIC DNA DAMAGE RESPONSE INHIBITORS TO INCREASE POTENCY IN HIGH-GRADE GLIOBLASTOMAS USING CLINICALLY RELEVANT EX-VIVO GLIOMA STEM CELL MODELS. Neuro-Oncology, 24(Supplement_7), vii93-vii93.
- Precision oncology using ex vivo technology: a step towards individualised cancer care?. Expert Reviews in Molecular Medicine, 24. View this article in WRRO
- DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.. Molecular Oncology, 16(1), 11-41. View this article in WRRO
- Tumour treating fields therapy for glioblastoma: current advances and future directions (vol 124, pg 697, 2020). BRITISH JOURNAL OF CANCER, 125(4), 623-623.
- O2: TOWARDS A LIVING BIOBANK OF SURGICALLY-RELEVANT 3-DIMENSIONAL GLIOBLASTOMA STEM CELL MODELS TO EVALUATE NOVEL THERAPEUTICS AND INTERROGATE INTRATUMOURAL HETEROGENEITY. British Journal of Surgery, 108(Supplement_1).
- Identification and validation of ERK5 as a DNA damage modulating drug target in glioblastoma. Cancers, 13(5). View this article in WRRO
- Tumour treating fields therapy for glioblastoma: current advances and future directions.. Br J Cancer, 124(4), 697-709.
- MRNIP is a replication fork protection factor.. Sci Adv, 6(28), eaba5974.
- EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7.. J Cell Sci, 133(9).
- RDNA-12. THE FANCONI ANAEMIA (FA) PATHWAY AND GLIOBLASTOMA: A NEW FOUNDATION FOR DNA DAMAGE RESPONSE TARGETED COMBINATIONS. Neuro-Oncology, 21(Supplement_6), vi209-vi209.
- TMOD-39. EX-VIVO 3-DIMENSIONAL MODELS OF POST-SURGICAL RESIDUAL DISEASE IN HUMAN GLIOBLASTOMA. Neuro-Oncology, 21(Supplement_6), vi271-vi271.
- The 'Ins and Outs' of Early Preclinical Models for Brain Tumor Research: Are They Valuable and Have We Been Doing It Wrong?. Cancers (Basel), 11(3).
- NOVEL DRUG TARGETS TO AUGMENT TEMOZOLOMIDE SENSITIVITY IN HIGH-GRADE BRAIN TUMOURS. NEURO-ONCOLOGY, 20, 346-346.
- P04.74 Preclinical evaluation of combinations targeting the DNA damage response in 2D and 3D models of glioblastoma stem cells. Neuro-Oncology, 20(suppl_3), iii297-iii297.
- The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response.. Oncotarget, 9(50), 29508-29524.
- The bornavirus-derived human protein EBLN1 promotes efficient cell cycle transit, microtubule organisation and genome stability.. Sci Rep, 6, 35548.
- Human CDK18 promotes replication stress signaling and genome stability.. Nucleic Acids Res, 44(18), 8772-8785.
- MRNIP/C5orf45 Interacts with the MRN Complex and Contributes to the DNA Damage Response.. Cell Rep, 16(10), 2565-2575.
- Ciliogenesis and the DNA damage response: a stressful relationship.. Cilia, 5, 19.
- OP21IDENTIFICATION OF NOVEL SMALL MOLECULE INHIBITORS OF THE FANCONI ANAEMIA DNA REPAIR PATHWAY AS A MEANS TO SENSITISES GLIOBLASTOMAS TO CHEMOTHERAPEUTIC AGENTS. Neuro-Oncology, 17(suppl 8), viii20.1-viii20.
- The leukemia-associated Rho guanine nucleotide exchange factor LARG is required for efficient replication stress signaling.. Cell Cycle, 13(21), 3450-3459.
- FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.. Oncotarget, 5(15), 6414-6424.
- Ccdc13 is a novel human centriolar satellite protein required for ciliogenesis and genome stability.. J Cell Sci, 127(Pt 13), 2910-2919.
- The centriolar satellite protein Cep131 is important for genome stability. Development, 140(2), e207-e207.
- The centriolar satellite protein Cep131 is important for genome stability.. J Cell Sci, 125(Pt 20), 4770-4779.
- CK2 phospho-dependent binding of R2TP complex to TEL2 is essential for mTOR and SMG1 stability.. Mol Cell, 39(6), 839-850.
- Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia.. Mol Cell, 39(1), 25-35.
- Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor.. PLoS One, 5(6), e11208.
- FANCM: fork pause, rewind and play.. EMBO J, 29(4), 703-705.
- FANCM-FAAP24 and HCLK2: roles in ATR signalling and the Fanconi anemia pathway.. Cell Cycle, 8(8), 1133-1137.
- DOG-1 is the Caenorhabditis elegans BRIP1/FANCJ homologue and functions in interstrand cross-link repair.. Mol Cell Biol, 28(5), 1470-1479.
- FANCM and FAAP24 function in ATR-mediated checkpoint signaling independently of the Fanconi anemia core complex.. Mol Cell, 32(3), 313-324.
- RTEL1 maintains genomic stability by suppressing homologous recombination.. Cell, 135(2), 261-271.
- Low-dose hyper-radiosensitivity: past, present, and future.. Int J Radiat Oncol Biol Phys, 70(5), 1310-1318.
- Transition in survival from low-dose hyper-radiosensitivity to increased radioresistance is independent of activation of ATM Ser1981 activity.. Int J Radiat Oncol Biol Phys, 69(4), 1262-1271.
- Emerging links between the biological clock and the DNA damage response.. Chromosoma, 116(4), 331-339.
- HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability.. Nat Cell Biol, 9(4), 391-401.
- Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. CANCER RES, 66(17), 8814-8821.
- C. elegans FANCD2 responds to replication stress and functions in interstrand cross-link repair.. DNA Repair (Amst), 5(11), 1398-1406.
- The life and death of DNA-PK.. Oncogene, 24(6), 949-961.
- Evasion of early cellular response mechanisms following low level radiation-induced DNA damage.. J Biol Chem, 279(48), 49624-49632.
- Enhanced radiation response through directed molecular targeting approaches.. Cancer Metastasis Rev, 23(3-4), 277-292.
- Hematopoietic progenitor stem cell homing in mice lethally irradiated with ionizing radiation at differing dose rates.. Radiat Res, 162(1), 48-55.
- Low-dose hyper-radiosensitivity: a consequence of ineffective cell cycle arrest of radiation-damaged G2-phase cells.. Radiat Res, 161(3), 247-255.
- Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy.. World J Urol, 21(4), 275-289.
- Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors.. Cancer Res, 63(7), 1550-1554.
- Expression of the DNA-PK binding protein E4-34K fails to confer radiation sensitivity to mammalian cells.. Int J Radiat Biol, 79(1), 53-60.
- Development of a novel rapid assay to assess the fidelity of DNA double-strand-break repair in human tumour cells.. Nucleic Acids Res, 30(2), E1.
- Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells.. Nucleic Acids Res, 29(7), 1534-1538.
- Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients. F1000Research, 12, 954-954.
Chapters
- Low dose hyper-radiosensitivity: A historical perspective, Targeted Radionuclide Tumor Therapy: Biological Aspects (pp. 329-347).
- Molecular targeting of DNA repair: A means to improve therapeutic index, New Research on DNA Repair (pp. 1-37).
Conference proceedings papers
- DEVELOPMENT OF GLIEXP; A HIGH-THROUGHPUT EX VIVO DRUG SCREENING PLATFORM FOR GLIOBLASTOMA. Neuro-Oncology, Vol. 25(Supplement_3) (pp iii5-iii6)
- F-1286: Ex vivo-led drug discovery in glioblastoma. Brain Tumor Research and Treatment, Vol. 10(Suppl) (pp s240). Seoul, Korea, 24 March 2022 - 24 March 2022. View this article in WRRO
- Tumour treating fields (TTFields) therapy for glioblastoma: a quantitative and qualitative summary of research and advances in our understanding. WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
- Patient-centric design of a neuro-oncology research primer to enhance communication and support of specimen donation for preclinical research. WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
- Development of unique ex vivo models of post-surgical residual glioblastoma. WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
- Combined inhibition of the Fanconi anaemia (FA) pathway and ATR promotes R-loop generation and profound radiosensitisation in glioblastoma. WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
- DNA damage response inhibitor combinations to enhance TTFields potency using clinically relevant ex-vivo glioblastoma models. WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
- FA-BASED COMBINATIONS TO TARGET THE DNA DAMAGE RESPONSE IN GLIOBLASTOMA. NEURO-ONCOLOGY, Vol. 20 (pp 358-358)
- PRECLINICAL EVALUATION OF COMBINATIONS TARGETING THE DNA DAMAGE RESPONSE IN 2D AND 3D MODELS OF GLIOBLASTOMA STEM CELLS. NEURO-ONCOLOGY, Vol. 20 (pp 297-297)
- View this article in WRRO Improving the Efficacy of Pulsed Radiation Therapy Using DNA Repair Inhibitors: A Preclinical Study. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol. 96(2) (pp E566-E567). Boston, Massachusetts, USA
- IDENTIFICATION OF NOVEL SMALL MOLECULE INHIBITORS OF THE FANCONI ANAEMIA DNA REPAIR PATHWAY AS A MEANS TO SENSITISES GLIOBLASTOMAS TO CHEMOTHERAPEUTIC AGENTS. NEURO-ONCOLOGY, Vol. 17 (pp 20-20)
- Optimization of siRNA-transgene expression in adenoviral vector systems for radiation sensitizing strategies. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol. 69(3) (pp S595-S596)
- HCLK2 couples FANCD2 to stalled replication forks and functions in the mammalian S-phase checkpoint. BREAST CANCER RESEARCH, Vol. 8 (pp S6-S6)
Preprints
- Inhibition of ATR opposes glioblastoma invasion through disruption of cytoskeletal networks and integrin internalisation via macropinocytosis, Research Square Platform LLC.
- Inhibition of ATR prevents macropinocytosis driven retraction of neurites and opposes invasion in GBM, Research Square Platform LLC.
- EML4-ALK V3 drives cell migration through NEK9 and NEK7 kinases in non-small-cell lung cancer, Cold Spring Harbor Laboratory.
- EML4-ALK V3 Drives Cell Migration Through NEK9 and NEK7 Kinases in Non-Small-Cell Lung Cancer.
- Research group
-
Research Group
- Dr. Katie Myers (Research Assistant/Lab Manager)
- Dr. Callum Jones (Postdoctoral Research Associate)
- Dr. Nikita Lad (Postdoctoral Research Associate)
- Dr. Sophie Williams (Clinical PhD Fellow)
- Connor McGarrity-Cottrell (PhD student)
- Hannah Gagg (PhD student with Dr. Greg Wells and Mr. Ola Rominiyi)
- Kelsey Wosnitzka (PhD student with Mr. Ola Rominiyi)
- Rebecca Livesey (PhD student with Prof. Fred Claeyssens)
- Tegan Torpey (PhD student with Mr. Ola Rominiyi and Prof. Fred Claeyssens)
- Teaching interests
-
M.Sc. Molecular Medicine
M.Sc. Translational Oncology
MSc Genomic Medicine